Skip to content

Author

C. Batlevi

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma

Data for the use of rituximab, gemcitabine, and oxaliplatin (R‐GemOx) for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record‐derived database comprising patient‐level data primarily from US community oncology practices.

L. Budde, A. Olszewski, Bei Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.